Coronavirus warning - does your poo look like this? Hidden signs of COVID-19 in the toilet
CORONAVIRUS symptoms include a high fever, a new cough, and loss of smell and taste. But you could also be at risk of COVID-19 infection if you notice a subtle change to your poo or toilet routine. Is diarrhoea a sign of coronavirus? (Source: Daily Express - Health)
Source: Daily Express - Health - May 31, 2020 Category: Consumer Health News Source Type: news
Coronavirus symptoms: Is diarrhoea a sign of Covid? What the officials say
CORONAVIRUS symptoms take a while to be verified by the health body in the UK. Is diarrhoea a sign of Covid? And where is this officially documented? (Source: Daily Express - Health)
Source: Daily Express - Health - May 29, 2020 Category: Consumer Health News Source Type: news
Rashes, headaches, tingling: the less common coronavirus symptoms that patients have
Studies have examined some of the more unusual signs of Covid-19Coronavirus – latest updatesSee all our coronavirus coverageThe World Health Organization lists the most common symptoms of Covid-19 as fever, tiredness and a dry cough. Others include a runny nose, sore throat, nasal congestion, pain, diarrhoea and the loss of sense of taste and/or smell. But there are also other more unusual symptoms that patients have presented.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - May 6, 2020 Category: Science Authors: Haroon Siddique Tags: Coronavirus outbreak World Health Organization Science Infectious diseases Source Type: news
Roche ’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1 – 7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint with 29% of infants (12/41; p<0.0001) sitting without support for five seconds by month 12, as assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III). No infants achieve this milestone in the natural history of Type 1 SMA. In addition, 18 (43.9%) infants were able to hold their head upright...
Source: Roche Media News - April 28, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA)
Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1 – 7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint with 29% of infants (12/41; p<0.0001) sitting without support for five seconds by month 12, as assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III). No infants achieve this milestone in the natural history of Type 1 SMA. In addition, 18 (43.9%) infants were able to hold their head upright...
Source: Roche Investor Update - April 28, 2020 Category: Pharmaceuticals Source Type: news
Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review
This new review is one of a series ofrapid reviews that Cochrane contributors have prepared to inform the 2020 COVID-19 pandemic.Some infectious diseases are spread by airborne droplets from coughs and sneezes, which can infect people who touch contaminated skin or surfaces. Washing hands with soap and water may prevent these diseases from spreading. People with no soap may use other materials like ash, mud, soil with or without water, or water alone, to clean their hands. Hand cleaning with ash (the solid remains from cooking stoves and fires) might work by rubbing away or inactivating the virus or bacteria. However, chem...
Source: Cochrane News and Events - April 24, 2020 Category: Information Technology Authors: Rachel Klabunde Source Type: news
Haunting Forest Spirits – is Mother Nature Striking Back?
By Jan LundiusSTOCKHOLM / ROME, Apr 20 2020 (IPS) Epidemic diseases are not random events that afflict societies capriciously and without warning, on the contrary, every society produces its own specific vulnerabilities. To study them is to understand the importance of a society’s structure, its standard of living, and its political priorities. […] Epidemics are a mirror, they show who we really are: Our ethics, beliefs, and socio-economic relationships.
&...
Source: IPS Inter Press Service - Health - April 20, 2020 Category: International Medicine & Public Health Authors: Jan Lundius Tags: Combating Desertification and Drought Economy & Trade Environment Global Globalisation Headlines Health Humanitarian Emergencies Natural Resources TerraViva United Nations Source Type: news
Coronavirus symptoms: Is a runny nose a sign? Expert reveals defining symptoms of COVID-19
CORONAVIRUS symptoms have been shown to manifest themselves in a number of ways, from diarrhoea to loss of sense of smell. But is a runny nose a sign of COVID-19? (Source: Daily Express - Health)
Source: Daily Express - Health - April 2, 2020 Category: Consumer Health News Source Type: news
Coronavirus symptoms: Is diarrhoea a symptom of coronavirus?
CORONAVIRUS cases are increasing every day, and if you show symptoms of coronavirus you must stay at home. So is diarrhoea a symptom of coronavirus? (Source: Daily Express - Health)
Source: Daily Express - Health - March 27, 2020 Category: Consumer Health News Source Type: news
Diarrhoea and loss of appetite could be early signs of coronavirus
A study of 204 patients in Wuhan, ground-zero for the COVID-19 outbreak, revealed people with digestive symptoms are harder to treat than those with just respiratory problems. (Source: the Mail online | Health)
Source: the Mail online | Health - March 20, 2020 Category: Consumer Health News Source Type: news
European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This is an im...
Source: Roche Media News - March 12, 2020 Category: Pharmaceuticals Source Type: news
European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This is an im...
Source: Roche Investor Update - March 12, 2020 Category: Pharmaceuticals Source Type: news
FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care for people ...
Source: Roche Investor Update - March 3, 2020 Category: Pharmaceuticals Source Type: news
Zimbabwe: Cuty in Fresh Typhoid Scare, Two Feared Dead
[New Zimbabwe] A Typhoid outbreak is suspected to have hit Gweru with two people confirmed dead due to diarrhoea infections. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 28, 2020 Category: African Health Source Type: news
Zimbabwe: City in Fresh Typhoid Scare, Two Feared Dead
[New Zimbabwe] A Typhoid outbreak is suspected to have hit Gweru with two people confirmed dead due to diarrhoea infections. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 28, 2020 Category: African Health Source Type: news
